Pfizer Reviews German Investment Over Drug Price Policies

CEO Albert Bourla warned Chancellor Friedrich Merz that government proposals to lower drug prices threaten long-term predictability. The company is now reviewing the timing and scope of its planned investments in Germany following similar pullbacks by Eli Lilly and Boehringer Ingelheim.